8-K: Nektar Reports Q2 2025 Results, Extends Cash Runway

Nektar Therapeutics announced its second quarter 2025 financial results, reporting decreased revenue and increased net loss, while extending its cash runway into Q1 2027 following a recent public offering.

Summary

• Cash and investments in marketable securities were $175.9 million on June 30, 2025, compared to $269.1 million on December 31, 2024.
• Approximate net proceeds of $107.5 million from a secondary offering closed on July 2, 2025, are not included in the June 30, 2025 cash balance.
• With the net proceeds from the secondary offering, Nektar expects its cash and investments to support operations into the first quarter of 2027.
• Revenue for the second quarter of 2025 was $11.2 million, a decrease from $23.5 million in the second quarter of 2024.
• Revenue for the first half of 2025 was $21.6 million, down from $45.1 million in the first half of 2024, primarily due to no longer recognizing product sales after the sale of the Huntsville manufacturing facility in December 2024.
• Total operating costs and expenses in the second quarter of 2025 were $47.4 million, a decrease from $73.3 million in the second quarter of 2024.
• Total operating costs and expenses in the first half of 2025 were $102.4 million, down from $130.3 million in the first half of 2024, driven by the elimination of cost of goods sold and decreased restructuring charges.
• Research and development (R&D) expense in the first half of 2025 increased to $60.4 million from $57.1 million in the first half of 2024, mainly due to increased development expenses for rezpegaldesleukin and NKTR-0165.
• General and administrative (G&A) expense in the first half of 2025 increased slightly to $41.4 million from $40.7 million in the first half of 2024, due to higher legal expenses.
• Net loss for the second quarter of 2025 was $41.6 million, or $2.95 basic and diluted loss per share, an improvement from a net loss of $52.4 million, or $3.76 basic and diluted loss per share, in the second quarter of 2024.
• Net loss for the first half of 2025 was $92.5 million, or $6.57 basic and diluted loss per share, compared to a net loss of $89.2 million, or $6.63 basic and diluted loss per share, in the first half of 2024.
• The U.S. Food and Drug Administration (FDA) granted Fast Track designation for rezpegaldesleukin for the treatment of severe-to-very severe alopecia areata in adults and pediatric patients 12 years and older in July 2025.
• The REZOLVE-AD study for rezpegaldesleukin in atopic dermatitis achieved statistical significance on the primary endpoint at week 16 for mean percent change in EASI score and key secondary endpoints in June 2025.
• Positive oral data for NKTR-255 as an adjunctive treatment to cell therapy in relapsed/refractory large B-cell lymphoma was presented at the 30th Annual European Hematological Association (EHA) Congress in June 2025.

Sentiment

Score: 7

Explanation: While revenue decreased due to a strategic asset sale, the company significantly extended its cash runway, reported positive clinical data for its lead asset (rezpegaldesleukin) in two indications, and received FDA Fast Track designation. The net loss also improved year-over-year for the quarter. These are strong operational and financial positives for a clinical-stage biotech, outweighing the revenue decline which was a planned outcome.

Positives

• Cash runway extended into the first quarter of 2027 following a successful public offering that raised $115 million in gross proceeds.
• Rezpegaldesleukin received FDA Fast Track designation for severe-to-very severe alopecia areata in adults and pediatric patients 12 years of age and older.
• The REZOLVE-AD Phase 2b study for rezpegaldesleukin in atopic dermatitis achieved statistical significance on its primary and key secondary endpoints at week 16, demonstrating rapid onset of EASI response and itch relief.
• Positive data for NKTR-255 as an adjunctive treatment to CAR T-cell therapy was presented, showing enhanced CAR T-cell expansion and durable complete responses.
• Net loss for Q2 2025 improved to $41.6 million from $52.4 million in Q2 2024.
• Total operating costs and expenses decreased significantly to $47.4 million in Q2 2025 from $73.3 million in Q2 2024.

Negatives

• Revenue significantly decreased to $11.2 million in Q2 2025 from $23.5 million in Q2 2024, and to $21.6 million in H1 2025 from $45.1 million in H1 2024, primarily due to the sale of the Huntsville manufacturing facility.
• Net loss for H1 2025 increased to $92.5 million from $89.2 million in H1 2024.
• Cash and investments in marketable securities decreased from $269.1 million on December 31, 2024, to $175.9 million on June 30, 2025, prior to the secondary offering proceeds.
• R&D expense increased in H1 2025 to $60.4 million from $57.1 million in H1 2024, driven by development of rezpegaldesleukin and NKTR-0165.
• G&A expense increased slightly in H1 2025 to $41.4 million from $40.7 million in H1 2024, due to higher legal expenses.
• Non-cash losses from the equity method investment in Gannet BioChem amounted to $2.4 million in Q2 2025 and $6.8 million in H1 2025.

Risks

• Statements regarding the therapeutic potential and future development plans for drug candidates are based on preclinical and clinical findings and observations and are subject to change as research and development continue.
• Rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422, and NKTR-255 are investigational agents, and continued research and development for these drug candidates is subject to substantial risks, including negative safety and efficacy findings in future clinical studies.
• Drug candidates are in clinical development, and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval.
• The timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval.
• A Fast Track designation does not increase the likelihood that rezpegaldesleukin will receive marketing approval in the United States.
• Patents may not issue from patent applications for drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required.
• Certain other important risks and uncertainties are set forth in the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 9, 2025.

Future Outlook

Nektar expects its cash and investments in marketable securities to support operations into the first quarter of 2027. The company anticipates reporting 52-week data from the Phase 2b study of rezpegaldesleukin in atopic dermatitis in early 2026 and data from a separate Phase 2b study in alopecia areata in December 2025. Nektar's goal is to advance its next T reg program, NKTR-0165, into the clinic in 2026 and is making significant progress on preclinical studies for a new bispecific antibody, NKTR-0166.

Management Comments

• "This quarter, we announced transformative data for rezpegaldesleukin from the Phase 2b study in patients with moderate to severe atopic dermatitis." Howard W. Robin, President and CEO.
• "The 16-week induction data demonstrated that rezpegaldesleukin resulted in a rapid onset of EASI response and itch relief and showcased the advantage of a broad-based Treg mechanism over other mechanistic approaches in development to treat atopic dermatitis." Howard W. Robin, President and CEO.
• "We look forward to seeing the effect of continued treatment with rezpegaldesleukin when we report the 52-week data in early 2026." Howard W. Robin, President and CEO.
• "In alopecia areata, we will report the data from a separate Phase 2b study in December of this year." Howard W. Robin, President and CEO.
• "We believe the data from both randomized studies will demonstrate the potential of rezpegaldesleukin to provide a new treatment paradigm for patients with chronic and serious diseases that significantly impact quality of life." Howard W. Robin, President and CEO.
• "As a first-in-class, T regulatory cell biologic, rezpegaldesleukin is poised to become an important novel mechanism to treat millions of patients with autoimmune disorders." Howard W. Robin, President and CEO.
• "We are proceeding in our IND-enabling studies for our next T reg program, NKTR-0165, which targets the TNFR2 receptor to stimulate tissue-specific T regulatory cells." Howard W. Robin, President and CEO.
• "Our goal is to advance NKTR-0165 into the clinic in 2026." Howard W. Robin, President and CEO.
• "Finally, we are making significant progress on advancing preclinical studies with a new bispecific antibody, NKTR-0166, which combines the TNFR2 epitope with a validated antibody target." Howard W. Robin, President and CEO.

Industry Context

Nektar's focus on developing first-in-class T regulatory cell stimulators like rezpegaldesleukin positions it in the highly competitive autoimmune and chronic inflammatory disease market. The positive Phase 2b data for atopic dermatitis and the FDA Fast Track designation for alopecia areata suggest potential differentiation in a field with significant unmet needs and numerous existing and emerging treatments. The advancement of NKTR-0165 and NKTR-0166 further strengthens its Treg-focused pipeline, aiming to introduce novel mechanisms of action. Additionally, the positive data for NKTR-255 in oncology highlights Nektar's broader therapeutic interests, potentially offering an advantage in combination therapies for cancer, aligning with the industry trend towards immuno-oncology and combination approaches.

Comparison to Industry Standards

• The filing highlights the 'advantage of a broad-based Treg mechanism over other mechanistic approaches in development to treat atopic dermatitis' for rezpegaldesleukin, but does not name specific comparable companies, projects, or their results.
• The data for NKTR-255 as an adjunctive treatment to cell therapy in relapsed/refractory large B-cell lymphoma showed 'Enhanced CAR T-cell Expansion and Durable Complete Responses,' which is a positive outcome in the competitive CAR T-cell therapy landscape, but no specific comparative benchmarks or competitor results are provided in the filing.

Stakeholder Impact

• Shareholders: The successful public offering and extended cash runway provide financial stability, while positive clinical data and FDA designation could increase long-term value. However, the offering also diluted existing shares.
• Patients: Positive clinical trial results for rezpegaldesleukin in atopic dermatitis and alopecia areata, along with Fast Track designation, offer hope for new treatment options for chronic and serious diseases.
• Employees: Continued progress in the pipeline and extended financial runway provide job security and a clear path for ongoing research and development.
• Partners: Positive data for NKTR-255 and ongoing collaborations reinforce the value of partnerships.

Next Steps

• Report 52-week data for rezpegaldesleukin in atopic dermatitis in early 2026.
• Report data from Phase 2b study of rezpegaldesleukin in alopecia areata in December 2025.
• Advance NKTR-0165 into the clinic in 2026.
• Continue advancing preclinical studies with NKTR-0166.
• Continue evaluating NKTR-255 in several ongoing clinical trials with partners.

Key Dates

Recommendation

The company has demonstrated significant progress in its clinical pipeline with positive Phase 2b data for rezpegaldesleukin and an FDA Fast Track designation, which are strong catalysts. The successful capital raise has also substantially extended the cash runway, mitigating immediate liquidity concerns. However, the company remains in a clinical-stage with no approved products generating significant revenue, and future clinical trial success is not guaranteed. The revenue decline, while explained by an asset sale, still highlights the lack of commercial products. The stock has seen a reverse split, which can sometimes indicate underlying challenges. Given the mix of strong clinical progress and improved financial stability against the inherent risks of biotech development, a 'Hold' recommendation is appropriate for investors to monitor upcoming data readouts and further pipeline advancement.

Keywords

Nektar Therapeutics, NKTR, biotechnology, clinical-stage, autoimmune diseases, chronic inflammatory diseases, rezpegaldesleukin, REZPEG, NKTR-358, atopic dermatitis, alopecia areata, T regulatory cell stimulator, NKTR-0165, TNFR2 receptor, NKTR-0166, bispecific antibody, NKTR-255, IL-15 receptor agonist, cancer therapy, financial results, Q2 2025, cash runway, FDA Fast Track, public offering, clinical trials, R&D, biopharma